Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.54 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498495 | 0.89 | RORC (0.57) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL7888069 | 0.89 | RORC (0.57) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL5110560 | 0.89 | RORC (0.57) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL4661703 | 0.89 | RORC (0.57) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL4661705 | 0.89 | RORC (0.57) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL23417389 | 0.89 | F10 (0.54) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL21413473 | 0.89 | F10 (0.54) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL24240396 | 0.89 | F10 (0.54) | F10PRSS1CCR5RORCSLC6A2 | |
| SCHEMBL320746 | 0.88 | RORC (0.55) | F10PRSS1RORCSLC6A2SLC6A4 | |
| SCHEMBL1804309 | 0.88 | F10 (0.53) | F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957450-B1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-06-24 | — | — | EP | disclosed |
| EP-1957450-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063009-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A2, SLC6A3 | F10 391/4885PRSS1 272/4885CCR5 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.